BASEL, Switzerland, Aug. 3 -- Cancer Immunology, Immunotherapy, a peer-reviewed journal that says it advances in the field of tumor immunology, published research articles on the following topics in its September 2024 edition (Vol. 73, Issue 9):

* Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients75 years: results of a real-world cohort including 456 patients

* Correction to: New CEACAM-targeting 2A3 single-domain antibody- . . .

Click here for more information about our products